Neurocysticercosis
17
1
1
10
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
17.6%
3 terminated out of 17 trials
76.9%
-9.6% vs benchmark
29%
5 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (17)
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
People Presenting With Neurocysticercosis in North America
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
A Pilot Study of Neurocysticercosis Treatment